UK Markets closed

Global Urothelial Cancer Drugs Market to Reach $8.2 Billion by 2027

ReportLinker
ReportLinker

In the changed post COVID-19 business landscape, the global market for Urothelial Cancer Drugs estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$8. 2 Billion by 2027, growing at aCAGR of 22.

New York, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Urothelial Cancer Drugs Industry" - https://www.reportlinker.com/p06033206/?utm_source=GNW
3% over the period 2020-2027. Immunotherapy, one of the segments analyzed in the report, is projected to record 21.9% CAGR and reach US$6.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 24.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $583.5 Million, While China is Forecast to Grow at 21.9% CAGR

The Urothelial Cancer Drugs market in the U.S. is estimated at US$583.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 21.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 19.8% and 19% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.4% CAGR.

Select Competitors (Total 42 Featured) -
AstraZeneca
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Co.
Exelixis, Inc
Genentech
GlaxoSmithKline
Merck
Novartis International AG
Pfizer


Read the full report: https://www.reportlinker.com/p06033206/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Urothelial Cancer Drugs - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Urothelial Cancer Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Urothelial Cancer Drugs
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 10: World Urothelial Cancer Drugs Market Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 11: USA Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 12: USA Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 13: USA 15-Year Perspective for Urothelial Cancer Drugs
by Treatment Class - Percentage Breakdown of Value Sales for
Immunotherapy and Chemotherapy for the Years 2012, 2021 & 2027

CANADA
Table 14: Canada Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 15: Canada Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 16: Canada 15-Year Perspective for Urothelial Cancer
Drugs by Treatment Class - Percentage Breakdown of Value Sales
for Immunotherapy and Chemotherapy for the Years 2012, 2021 &
2027

JAPAN
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 17: Japan Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 18: Japan Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 19: Japan 15-Year Perspective for Urothelial Cancer Drugs
by Treatment Class - Percentage Breakdown of Value Sales for
Immunotherapy and Chemotherapy for the Years 2012, 2021 & 2027

CHINA
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 20: China Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 21: China Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 22: China 15-Year Perspective for Urothelial Cancer Drugs
by Treatment Class - Percentage Breakdown of Value Sales for
Immunotherapy and Chemotherapy for the Years 2012, 2021 & 2027

EUROPE
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 23: Europe Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2020 through 2027 and %
CAGR

Table 24: Europe Historic Review for Urothelial Cancer Drugs by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 25: Europe 15-Year Perspective for Urothelial Cancer
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2021 & 2027

Table 26: Europe Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 27: Europe Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 28: Europe 15-Year Perspective for Urothelial Cancer
Drugs by Treatment Class - Percentage Breakdown of Value Sales
for Immunotherapy and Chemotherapy for the Years 2012, 2021 &
2027

FRANCE
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 29: France Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 30: France Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 31: France 15-Year Perspective for Urothelial Cancer
Drugs by Treatment Class - Percentage Breakdown of Value Sales
for Immunotherapy and Chemotherapy for the Years 2012, 2021 &
2027

GERMANY
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 32: Germany Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 33: Germany Historic Review for Urothelial Cancer Drugs
by Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 34: Germany 15-Year Perspective for Urothelial Cancer
Drugs by Treatment Class - Percentage Breakdown of Value Sales
for Immunotherapy and Chemotherapy for the Years 2012, 2021 &
2027

ITALY
Table 35: Italy Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 36: Italy Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 37: Italy 15-Year Perspective for Urothelial Cancer Drugs
by Treatment Class - Percentage Breakdown of Value Sales for
Immunotherapy and Chemotherapy for the Years 2012, 2021 & 2027

UNITED KINGDOM
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 38: UK Recent Past, Current & Future Analysis for
Urothelial Cancer Drugs by Treatment Class - Immunotherapy and
Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 39: UK Historic Review for Urothelial Cancer Drugs by
Treatment Class - Immunotherapy and Chemotherapy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 40: UK 15-Year Perspective for Urothelial Cancer Drugs by
Treatment Class - Percentage Breakdown of Value Sales for
Immunotherapy and Chemotherapy for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 41: Rest of Europe Recent Past, Current & Future Analysis
for Urothelial Cancer Drugs by Treatment Class - Immunotherapy
and Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 42: Rest of Europe Historic Review for Urothelial Cancer
Drugs by Treatment Class - Immunotherapy and Chemotherapy
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 43: Rest of Europe 15-Year Perspective for Urothelial
Cancer Drugs by Treatment Class - Percentage Breakdown of Value
Sales for Immunotherapy and Chemotherapy for the Years 2012,
2021 & 2027

ASIA-PACIFIC
Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 44: Asia-Pacific Recent Past, Current & Future Analysis
for Urothelial Cancer Drugs by Treatment Class - Immunotherapy
and Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 45: Asia-Pacific Historic Review for Urothelial Cancer
Drugs by Treatment Class - Immunotherapy and Chemotherapy
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 46: Asia-Pacific 15-Year Perspective for Urothelial
Cancer Drugs by Treatment Class - Percentage Breakdown of Value
Sales for Immunotherapy and Chemotherapy for the Years 2012,
2021 & 2027

REST OF WORLD
Table 47: Rest of World Recent Past, Current & Future Analysis
for Urothelial Cancer Drugs by Treatment Class - Immunotherapy
and Chemotherapy - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 48: Rest of World Historic Review for Urothelial Cancer
Drugs by Treatment Class - Immunotherapy and Chemotherapy
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 49: Rest of World 15-Year Perspective for Urothelial
Cancer Drugs by Treatment Class - Percentage Breakdown of Value
Sales for Immunotherapy and Chemotherapy for the Years 2012,
2021 & 2027

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06033206/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001